Phio Pharmaceuticals Corp represents innovation, commitment, and excellence in the field of biotechnology. The company's corporate philosophy revolves around advancing the development of RNA-based therapeutics to address unmet medical needs. Phio Pharmaceuticals Corp strives to improve patients' lives by harnessing the power of RNA interference, enabling targeted gene silencing and modulation. With a strong focus on research and development, the company seeks to revolutionize the treatment of various diseases, including cancer and inflammatory disorders. By constantly pushing boundaries and utilizing cutting-edge technologies, Phio Pharmaceuticals Corp aims to bring groundbreaking therapies to patients worldwide.

Phio Pharmaceuticals Corp primarily operates in the United States.

Phio Pharmaceuticals Corp, a distinguished biotechnology company, has successfully reached numerous significant milestones. Notably, Phio Pharmaceuticals Corp attained important accomplishments such as advancing its innovative RNAi technology platform and expanding its intellectual property portfolio. Moreover, the company has successfully completed preclinical studies, showcasing the potential of its RNA-based therapeutics in various therapeutic areas. Through strategic collaborations and partnerships, Phio Pharmaceuticals Corp has strengthened its position in the competitive biotech industry. With a strong focus on research and development, the company continues to make remarkable progress in advancing novel RNAi-based treatments, thereby fostering hope for improved healthcare outcomes.

Phio Pharmaceuticals Corp is a company with a rich history and promising future. Established in [insert year], Phio Pharmaceuticals Corp has emerged as a key player in the field of biotechnology. The company focuses on developing innovative RNA therapeutics to address unmet medical needs. With a team of dedicated scientists and researchers, Phio Pharmaceuticals Corp has achieved significant milestones in advancing RNA interference technology. Their cutting-edge research has paved the way for potential treatments in various disease areas, such as cancer, genetic disorders, and viral infections. As a leading biotech organization, Phio Pharmaceuticals Corp continues to strive for breakthroughs in the field of RNA therapeutics, holding great potential for medical advancements and improving patients' lives.

The main competitors of Phio Pharmaceuticals Corp in the market include notable pharmaceutical companies such as Novartis AG, Pfizer Inc., Johnson & Johnson, and Roche Holding AG.

Phio Pharmaceuticals Corp is primarily active in the biopharmaceutical industry.

The business model of Phio Pharmaceuticals Corp focuses on developing novel RNA therapeutics to treat various diseases. They specialize in harnessing the power of RNA interference (RNAi) and oligonucleotide-based therapeutics to selectively silence disease-causing genes. By targeting specific genes responsible for disease progression, Phio Pharmaceuticals aims to enhance the body's natural defense mechanisms and provide innovative treatment options for patients. With a strong emphasis on research and development, Phio Pharmaceuticals is committed to advancing its pipeline of RNA-based therapies to address unmet medical needs and improve patient outcomes.

Phio Pharmaceuticals P/E-luku on −0,38.

Phio Pharmaceuticals KUV on 0,05.

AlleAktien Laatuscore Phio Pharmaceuticals on 2/10.

odotettu Phio Pharmaceuticals liikevaihto on 112,50 milj. USD.

odotettu Phio Pharmaceuticals voitto on −14,37 milj. USD.

The company Phio Pharmaceuticals Corp specializes in the development and commercialization of therapies for the treatment of cancer and chronic infections. Their business model is based on utilizing their own technology platforms to develop, patent, and market innovative therapies. Phio's main technology platform is called "Self-Delivering RNAi (sd-rxRNA)". This technology allows for targeted suppression of specific genes associated with diseases such as cancer and infections. It is based on the use of Ribonucleic acid (RNA) as a therapeutic agent, with Phio using a proprietary form of RNA that can penetrate cells and exert its effects without the need for additional transfection agents or vectors. In recent years, Phio has focused on developing therapies for rare and difficult-to-treat forms of cancer. They are currently working on several product candidates in various stages of clinical development, with their lead candidate being "PH-762", an sd-rxRNA therapy for pleural-pulmonary malignant mesothelioma (PPM), a rare form of lung cancer. Phio has already published promising Phase I clinical data for PH-762, demonstrating good tolerability and efficacy. Phio has also entered into an agreement with the National Institutes of Health (NIH) in the United States to further develop its technology platforms and products. The company aims to collaborate with the NIH and other partners to develop new therapies for viral and bacterial infections, as well as rare diseases. To enhance its technology platforms and accelerate product development, Phio has also made targeted acquisitions and licensing agreements in recent years. In 2018, they acquired RXi Pharmaceuticals to expand their sd-rxRNA technology platform. Additionally, Phio has entered into several strategic partnerships with other companies to gain access to new technology platforms and product candidates. Phio operates on a business-to-business (B2B) model, licensing or selling its products and technology platforms to other pharmaceutical and biotech companies. They have already established multiple partnerships and licensing agreements to market their sd-rxRNA technology platform and products. For example, Phio has partnered with Glycostem Therapeutics to utilize the sd-rxRNA technology platform for the production of product candidates for cancer immunotherapy. Overall, Phio's business model relies on utilizing its own technology platforms to develop innovative therapies for cancer and infections. The company focuses on developing therapies for rare forms of cancer and has already published Phase I clinical data for their lead product candidate. Phio has also formed several partnerships to gain access to new technology platforms and product candidates, and operates on a B2B model, licensing or selling their products and technology platforms to other companies.

Phio Pharmaceuticals maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Phio Pharmaceuticals:lle tai yhtiö ei maksa osinkoa.

Phio Pharmaceuticals:n ISIN on US71880W3034.

Phio Pharmaceuticals:n WKN on A2PYB0.

Phio Pharmaceuticals:n tunnus on PHIO.

Viimeisen 12 kuukauden aikana Phio Pharmaceuticals maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Phio Pharmaceuticals maksanee ennusteiden mukaan 0 USD osingon.

Phio Pharmaceuticals:n tämänhetkinen osinkotuotto on .

Phio Pharmaceuticals maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Phio Pharmaceuticals maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Phio Pharmaceuticals kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Phio Pharmaceuticals osingon 8.9.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 8.9.2024.

Viimeisin osinko maksettiin 8.9.2024.

Vuonna 2023 Phio Pharmaceuticals maksoi 0 USD osinkoina.

Phio Pharmaceuticals:n osingot maksetaan USDssa.